SCHEMBL24907177

SCHEMBL24907177

C[Si](C)(C)OC1(c2ccc(F)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A2 P23975 2/20 0.36
MAOB P27338 2/20 0.35
MAOA P21397 1/20 0.35
CHRNA1 P02708 1/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
CHRND Q07001 1/20 0.33
HSD11B1 P28845 2/20 0.32
OPRM1 P35372 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
PABPC1 P11940 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12078583 0.80 ALOX5 (0.33) SLC6A3SLC6A2CHRNA1CHRNGCHRNB1
SCHEMBL747119 0.71 SLC6A4 (0.33) SLC6A3SLC6A4
SCHEMBL697114 0.69 MAOB (0.36) SLC6A3SLC6A4SLC6A2MAOBMAOA
SCHEMBL9035464 0.69 DRD2 (0.38) SLC6A3SLC6A4OPRM1MEN1LMNA
SCHEMBL18019005 0.68 LIPG (0.44) SLC6A3SLC6A4SLC6A2MAOBMAOA
SCHEMBL27887266 0.68 SLC6A3 (0.47) SLC6A3SLC6A4SLC6A2MAOBMAOA
Hydrochloric Acid SCHEMBL3251166 0.64 LIPG (0.39) SLC6A3SLC6A4SLC6A2HSD11B1OPRM1
SCHEMBL8071001 0.64 DRD2 (0.50) SLC6A3SLC6A4OPRM1KMT2ASMN1; SMN2
SCHEMBL6889536 0.64 LIPG (0.42) SLC6A3SLC6A4SLC6A2HSD11B1OPRM1
SCHEMBL9230998 0.64 MAOB (0.43) SLC6A3SLC6A4SLC6A2MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4165023-A1 INHIBITORS OF APOL1 AND USE OF THE SAME Vertex Pharmaceuticals Incorporated (US) 2023-04-19 EP disclosed
CN-115867532-A Inhibitors of APOL1 and uses thereof 弗特克斯药品有限公司 2023-03-28 CN disclosed
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 SLC6A3 2627/4885SLC6A4 4252/4885SLC6A2 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.